Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Dec;37(12):2727–2732. doi: 10.1128/aac.37.12.2727

Increased renal uptake of gentamicin in endotoxemic rats receiving concomitant thromboxane A2 antagonist therapy.

M Tardif 1, Y Bergeron 1, D Beauchamp 1, M G Bergeron 1
PMCID: PMC192792  PMID: 8109943

Abstract

This report describes the effects of endotoxin and a thromboxane receptor antagonist, L-655,240, on kidney function and the intrarenal pharmacokinetics of aminoglycosides. The rationale for these studies was that thromboxane antagonists may eventually be used in combination with aminoglycosides in patients with gram-negative sepsis and endotoxemia. As aminoglycosides are nephrotoxic and endotoxin has already been shown to increase the renal uptake of gentamicin, we investigated the possibility that thromboxane antagonists might interfere with the nephrotoxic potential of both substances. A decrease in the volume of distribution and an increase in the intracortical concentration of gentamicin were observed in animals given endotoxin. Compared with animals given endotoxin alone, those which received endotoxin plus L-655,240 had significant accumulation of gentamicin in the renal cortex and medulla, as determined by the area under the concentration-time curve, and a significant reduction in the total clearance of the antibiotic (P < 0.05). This difference in uptake could not be attributed to hypotension or changes in the glomerular filtration rate or renal plasma flow. L-655,240 alone did not modify gentamicin pharmacokinetics but did decrease p-aminohippuric acid secretion. Thromboxane antagonists in the context of endotoxemia increase intrarenal uptake of aminoglycosides. If these compounds are to be used as therapeutic agents when endotoxin is present, their influence on renal handling of nephrotoxic drugs needs to be considered. Multiple-dosing regimens deserve investigation.

Full text

PDF
2727

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atzori L., Olafsdóttir K., Corriga A. M., Bannenberg G., Ryrfeldt A., Moldéus P. Thiol modification in H2O2- and thromboxane-induced vaso- and bronchoconstriction in rat perfused lung. J Appl Physiol (1985) 1991 Oct;71(4):1309–1314. doi: 10.1152/jappl.1991.71.4.1309. [DOI] [PubMed] [Google Scholar]
  2. Aubert-Tulkens G., Van Hoof F., Tulkens P. Gentamicin-induced lysosomal phospholipidosis in cultured rat fibroblasts. Quantitative ultrastructural and biochemical study. Lab Invest. 1979 Apr;40(4):481–491. [PubMed] [Google Scholar]
  3. Auclair P., Tardif D., Beauchamp D., Gourde P., Bergeron M. G. Prolonged endotoxemia enhances the renal injuries induced by gentamicin in rats. Antimicrob Agents Chemother. 1990 May;34(5):889–895. doi: 10.1128/aac.34.5.889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Badr K. F., Kelley V. E., Rennke H. G., Brenner B. M. Roles for thromboxane A2 and leukotrienes in endotoxin-induced acute renal failure. Kidney Int. 1986 Oct;30(4):474–480. doi: 10.1038/ki.1986.210. [DOI] [PubMed] [Google Scholar]
  5. Beauchamp D., Laurent G., Maldague P., Abid S., Kishore B. K., Tulkens P. M. Protection against gentamicin-induced early renal alterations (phospholipidosis and increased DNA synthesis) by coadministration of poly-L-aspartic acid. J Pharmacol Exp Ther. 1990 Nov;255(2):858–866. [PubMed] [Google Scholar]
  6. Beauchamp D., Pellerin M., Gourde P., Pettigrew M., Bergeron M. G. Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats. Antimicrob Agents Chemother. 1990 Jan;34(1):139–147. doi: 10.1128/aac.34.1.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Beauchamp D., Poirier A., Bergeron M. G. Increased nephrotoxicity of gentamicin in pyelonephritic rats. Kidney Int. 1985 Aug;28(2):106–113. doi: 10.1038/ki.1985.128. [DOI] [PubMed] [Google Scholar]
  8. Bergeron M. G., Bergeron Y. Influence of endotoxin on the intrarenal distribution of gentamicin, netilmicin, tobramycin, amikacin, and cephalothin. Antimicrob Agents Chemother. 1986 Jan;29(1):7–12. doi: 10.1128/aac.29.1.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bergeron M. G., Bergeron Y., Marois Y. Autoradiography of tobramycin uptake by the proximal and distal tubules of normal and endotoxin-treated rats. Antimicrob Agents Chemother. 1986 Jun;29(6):1005–1009. doi: 10.1128/aac.29.6.1005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bergeron M. G., Marois Y., Kuehn C., Silverblatt F. J. Autoradiographic study of tobramycin uptake by proximal and distal tubules of normal and pyelonephritic rats. Antimicrob Agents Chemother. 1987 Sep;31(9):1359–1364. doi: 10.1128/aac.31.9.1359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bergeron M. G., Trottier S. Influence of single or multiple doses of gentamicin and netilmicin on their cortical, medullary, and papillary distribution. Antimicrob Agents Chemother. 1979 May;15(5):635–641. doi: 10.1128/aac.15.5.635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Bottoms G. D., Templeton C. B., Fessler J. F., Johnson M. A., Roesel O. F., Ewert K. M., Adams S. B. Thromboxane, prostaglandin I2 (epoprostenol), and the hemodynamic changes in equine endotoxin shock. Am J Vet Res. 1982 Jun;43(6):999–1002. [PubMed] [Google Scholar]
  13. Bunke M., Wilder L., Martin A. Protection of glomerular filtration rate by the thromboxane receptor antagonist L655,240 during low dose cyclosporine administration. Prostaglandins. 1992 Apr;43(4):351–360. doi: 10.1016/0090-6980(92)90035-r. [DOI] [PubMed] [Google Scholar]
  14. Burger R., Fung D., Bryan A. C. Lung injury in a surfactant-deficient lung is modified by indomethacin. J Appl Physiol (1985) 1990 Dec;69(6):2067–2071. doi: 10.1152/jappl.1990.69.6.2067. [DOI] [PubMed] [Google Scholar]
  15. Cirino M., Morton H., MacDonald C., Hadden J., Ford-Hutchinson A. W. Thromboxane A2 and prostaglandin endoperoxide analogue effects on porcine renal blood flow. Am J Physiol. 1990 Jan;258(1 Pt 2):F109–F114. doi: 10.1152/ajprenal.1990.258.1.F109. [DOI] [PubMed] [Google Scholar]
  16. Cook J. A., Wise W. C., Halushka P. V. Elevated thromboxane levels in the rat during endotoxic shock: protective effects of imidazole, 13-azaprostanoic acid, or essential fatty acid deficiency. J Clin Invest. 1980 Jan;65(1):227–230. doi: 10.1172/JCI109655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Farman N., Pradelles P., Bonvalet J. P. PGE2, PGF2 alpha, 6-keto-PGF1 alpha, and TxB2 synthesis along the rabbit nephron. Am J Physiol. 1987 Jan;252(1 Pt 2):F53–F59. doi: 10.1152/ajprenal.1987.252.1.F53. [DOI] [PubMed] [Google Scholar]
  18. Fried V. A., Rothfield L. I. Interactions between lipopolysaccharide and phosphatidylethanolamine in molecular monolayers. Biochim Biophys Acta. 1978 Dec 4;514(1):69–82. doi: 10.1016/0005-2736(78)90077-9. [DOI] [PubMed] [Google Scholar]
  19. Hall R. A., Gillard J., Guindon Y., Letts G., Champion E., Ethier D., Evans J., Ford-Hutchinson A. W., Fortin R., Jones T. R. Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpro pan oic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonist. Eur J Pharmacol. 1987 Mar 17;135(2):193–201. doi: 10.1016/0014-2999(87)90611-x. [DOI] [PubMed] [Google Scholar]
  20. Hall S. E. Thromboxane A2 receptor antagonists. Med Res Rev. 1991 Sep;11(5):503–579. doi: 10.1002/med.2610110504. [DOI] [PubMed] [Google Scholar]
  21. Harlan J., Winn R., Hildebrandt J., Harker L. Selective inhibition of thromboxane synthesis during experimental endotoxemia in the goat: effects on pulmonary haemodynamics and lung lymph flow. Br J Clin Pharmacol. 1983;15 (Suppl 1):123S–126S. doi: 10.1111/j.1365-2125.1983.tb02122.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hébert R. L., Sirois P., Plante G. E. Inhibition of platelet-activating factor induced renal hemodynamic and tubular dysfunctions with L-655,240, a new thromboxane-prostaglandin endoperoxide antagonist. Can J Physiol Pharmacol. 1989 Apr;67(4):304–308. doi: 10.1139/y89-049. [DOI] [PubMed] [Google Scholar]
  23. Joly V., Bergeron Y., Bergeron M. G., Carbon C. Endotoxin-tobramycin additive toxicity on renal proximal tubular cells in culture. Antimicrob Agents Chemother. 1991 Feb;35(2):351–357. doi: 10.1128/aac.35.2.351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kilbourn R. G., Griffith O. W. Overproduction of nitric oxide in cytokine-mediated and septic shock. J Natl Cancer Inst. 1992 Jun 3;84(11):827–831. doi: 10.1093/jnci/84.11.827. [DOI] [PubMed] [Google Scholar]
  25. Levitt M. A., Stahl G., Lefer A. M. Efficacy of a combination thromboxane receptor antagonist and lipoxygenase inhibitor in traumatic shock. Resuscitation. 1988 Jul;16(3):211–220. doi: 10.1016/0300-9572(88)90047-0. [DOI] [PubMed] [Google Scholar]
  26. Lianos E. A., Andres G. A., Dunn M. J. Glomerular prostaglandin and thromboxane synthesis in rat nephrotoxic serum nephritis. Effects on renal hemodynamics. J Clin Invest. 1983 Oct;72(4):1439–1448. doi: 10.1172/JCI111100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Mann W. A., Welzel G. E., Goldstein R. S., Sozio R. S., Cyronak M. J., Kao J., Kinter L. B. Characterization of the renal effects and renal elimination of sulotroban in the dog. J Pharmacol Exp Ther. 1991 Dec;259(3):1231–1240. [PubMed] [Google Scholar]
  28. Mathison J. C., Ulevitch R. J. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol. 1979 Nov;123(5):2133–2143. [PubMed] [Google Scholar]
  29. Moncada S., Higgs E. A. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur J Clin Invest. 1991 Aug;21(4):361–374. doi: 10.1111/j.1365-2362.1991.tb01383.x. [DOI] [PubMed] [Google Scholar]
  30. Ngeleka M., Beauchamp D., Tardif D., Auclair P., Gourde P., Bergeron M. G. Endotoxin increases the nephrotoxic potential of gentamicin and vancomycin plus gentamicin. J Infect Dis. 1990 Apr;161(4):721–727. doi: 10.1093/infdis/161.4.721. [DOI] [PubMed] [Google Scholar]
  31. Ogletree M. L., Allen G. T. Interspecies differences in thromboxane receptors: studies with thromboxane receptor antagonists in rat and guinea pig smooth muscles. J Pharmacol Exp Ther. 1992 Feb;260(2):789–794. [PubMed] [Google Scholar]
  32. Ogletree M. L. Overview of physiological and pathophysiological effects of thromboxane A2. Fed Proc. 1987 Jan;46(1):133–138. [PubMed] [Google Scholar]
  33. Okegawa T., DeSchryver-Kecskemeti K., Needleman P. Endotoxin induces chronic prostaglandin and thromboxane synthesis from ureter-obstructed kidneys: role of inflammatory cells. J Pharmacol Exp Ther. 1983 Apr;225(1):213–218. [PubMed] [Google Scholar]
  34. Perico N., Zoja C., Benigni A., Ghilardi F., Gualandris L., Remuzzi G. Effect of short-term cyclosporine administration in rats on renin-angiotensin and thromboxane A2: possible relevance to the reduction in glomerular filtration rate. J Pharmacol Exp Ther. 1986 Oct;239(1):229–235. [PubMed] [Google Scholar]
  35. Sakr H. M., Dunham E. W. Mechanism of arachidonic acid-induced vasoconstriction in the intact rat kidney: possible involvement of thromboxane A2. J Pharmacol Exp Ther. 1982 Jun;221(3):614–622. [PubMed] [Google Scholar]
  36. Samuelsson B., Goldyne M., Granström E., Hamberg M., Hammarström S., Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem. 1978;47:997–1029. doi: 10.1146/annurev.bi.47.070178.005025. [DOI] [PubMed] [Google Scholar]
  37. Shenep J. L., Barton R. P., Mogan K. A. Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental gram-negative bacterial sepsis. J Infect Dis. 1985 Jun;151(6):1012–1018. doi: 10.1093/infdis/151.6.1012. [DOI] [PubMed] [Google Scholar]
  38. Tune B. M., Hsu C. Y. Augmentation of antibiotic nephrotoxicity by endotoxemia in the rabbit. J Pharmacol Exp Ther. 1985 Aug;234(2):425–430. [PubMed] [Google Scholar]
  39. Wise W. C., Cook J. A., Halushka P. V., Knapp D. R. Protective effects of thromboxane synthetase inhibitors in rats in endotoxic shock. Circ Res. 1980 Jun;46(6):854–859. doi: 10.1161/01.res.46.6.854. [DOI] [PubMed] [Google Scholar]
  40. Zager R. A., Prior R. B. Gentamicin and gram-negative bacteremia. A synergism for the development of experimental nephrotoxic acute renal failure. J Clin Invest. 1986 Jul;78(1):196–204. doi: 10.1172/JCI112552. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES